The diagnosis of LCAT deficiency was established with a combination of clinical and pathological findings.<h4>Conclusions</h4>Currently renal prognosis is poor but conservative management with ACE inhibitors and lipid lowering therapy in addition to steroids has been shown to retard progression to end-stage renal disease. This evidence concerns the gene LCAT and chronic kidney disease.